SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 461.65 |
| Enterprise Value ($M) | 466.78 |
| Book Value ($M) | 199.35 |
| Book Value / Share | 1.16 |
| Price / Book | 2.32 |
| NCAV ($M) | 186.93 |
| NCAV / Share | 1.09 |
| Price / NCAV | 2.47 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.37 |
| Return on Assets (ROA) | -0.47 |
| Return on Equity (ROE) | -0.59 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 17.70 |
| Current Ratio | 17.70 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 226.40 |
| Assets | 238.82 |
| Liabilities | 39.47 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Vestal Point Capital, LP | |||
| 13G/A | Farallon Capital Partners, L.P. | |||
| 13G/A | Wellington Management Group Llp | |||
| 13G | Frazier Life Sciences Public Fund, L.P. | 5.00 | ||
| 13G/A | Prudential Financial Inc | 4.50 | -24.29 | |
| 13G/A | Adage Capital Management, L.P. | 4.10 | ||
| 13G/A | Jennison Associates Llc | 4.10 | -23.62 | |
| 13G | BlackRock, Inc. | 5.70 | 0.00 | |
| 13D/A | Growth Equity Opportunities 17, LLC | 14.90 | 0.00 | |
| 13D/A | Bain Capital Life Sciences Fund II, L.P. | 9.99 | 2.34 | |
| 13G/A | Venrock Healthcare Capital Partners II, L.P. | 2.60 | -44.90 | |
| 13G/A | Zambon Spa | 3.46 | -0.29 | |
| 13G/A | Caxton Corp | 0.30 | -94.88 | |
| 13G/A | Adage Capital Partners Gp, L.l.c. | 5.64 | 11.27 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| Form 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 144,418 | 549,642 | 26.27 | |
| 96,040 | 343,244 | 27.98 | |
| 118,288 | 365,542 | 32.36 | |
| 128,550 | 434,732 | 29.57 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| SRRK – Scholar Rock Holding Corporation | STOK – Stoke Therapeutics, Inc. |
| STTK – Shattuck Labs, Inc. | SWTX – SpringWorks Therapeutics, Inc. |
| SYRE – Spyre Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io